FDA greenlights Incyte and Syndax’s GvHD drug Niktimvo
The US Food and Drug Administration (FDA) has approved Incyte and Syndax Pharmaceuticals’ antibody therapy, Niktimvo (axatilimab-csfr), as a third-line…
Immunology
-
-
Acelyrin deprioritises lead therapy despite Phase III win, fires 33% of staff
Acelyrin has decided to shake up its pipeline; while the company touted positive Phase III data for izokibep in hidradenitis…
-
FDA approves IASO Bio’s IND for equecabtagene autoleucel
IASO Biotherapeutics has secured US Food and Drug Administration (FDA) approval for its investigational new drug (IND) application for equecabtagene…
-
Cue Biopharma downsizes to focus on autoimmune pipeline
Cue Biopharma has instituted strategic restructuring measures with a plan to focus on autoimmune programmes and carry out a workforce…
-
Sandoz launches ustekinumab biosimilar in Europe
Sandoz has announced the European launch of Pyzchiva, a ustekinumab biosimilar approved for the treatment of several autoimmune conditions including…
-
Pipeline power: Sionna’s AbbVie deal could redefine CF therapeutics
Sionna Therapeutics, a biopharmaceutical company dedicated to advancing treatments for cystic fibrosis (CF), has significantly strengthened its position in the…
-
Boehringer Ingelheim offers Humira biosimilar at 92% discount
Boehringer Ingelheim will sell an unbranded version AbbVie’s reference drug at a 92% discount to gain traction in the Humira…
-
AbbVie looks to add a ninth indication for JAK inhibitor Rinvoq
AbbVie is set to expand the indication list for its immunology blockbuster, Rinvoq (upadacitinib). The company has submitted applications to…
-
Conflict means millions of children are missing vaccinations, UN says
A joint report by United Nations (UN) agencies has revealed that global immunisation coverage has stalled, remaining largely unchanged from…
-
SciRhom secures $70m for autoimmune diseases treatments
German biopharmaceutical company SciRhom has secured €63m ($70m) in a Series A funding round to expedite the development of iRhom2-targeting…
